Download presentation
1
Suvorexant for Insomnia
Funding At least partial NINDS or NIH support Other FDA approves suvorexant for insomnia Narcoleptic patients have profound decrease in CSF orexin Both orexin receptors are required for wakefulness Dual orexin receptor antagonist (suvorexant) induces sleep in rats, dogs, humans Canine narcolepsy caused by mutations in orexin receptors Clinical trials demonstrate safety and efficacy of suvorexant Discovery of orexin peptide and receptor family Dirunal variation of CSF orexin levels in humans 2000s 2010s
2
Enzyme Replacement for Gaucher Disease
Funding At least partial NINDS or NIH support Other Large scale enzyme purification technique developed First clinical trials show enzyme replacement safe and effective Dr. Roscoe Brady, NINDS IRP receives National Medal of Technology and Innovation Glucocerebrosid-ase localized to lysosomes FDA approves glucocerebrosidase for Gaucher disease One of first commercially successful enzyme replacement therapies First patients treated with enzyme purified from human placenta Discovery of method to localize enzyme to lysosome Gaucher patients are deficient in glucocerebrosidase 1960s 1970s 1980s 1990s
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.